|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
109,640,000 |
Market
Cap: |
62.71(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.54 - $2.19 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 4.2 |
Insider 6 Months : 4.9 |
Insider 3/6 Months : 9.5 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Viaskin. Co.'s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. Co.'s lead product candidate, Viaskin Peanut, has completed a global Phase III program for the treatment of peanut-allergic patients four to 11 years of age. Co.'s second product candidate, Viaskin Milk, is in development for the treatment of cow's milk protein allergy children two to 17 years of age.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
17,094 |
18,919 |
45,919 |
45,919 |
Total Buy Value |
$14,188 |
$15,812 |
$58,352 |
$58,352 |
Total People Bought |
1 |
2 |
4 |
4 |
Total Buy Transactions |
1 |
2 |
4 |
4 |
Total Shares Sold |
1,042 |
1,042 |
3,287 |
5,548 |
Total Sell Value |
$1,425 |
$1,425 |
$5,331 |
$12,152 |
Total People Sold |
1 |
1 |
1 |
1 |
Total Sell Transactions |
2 |
2 |
3 |
5 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mohideen Pharis |
Chief Medical Officer |
|
2024-05-24 |
4 |
S |
$1.36 |
$898 |
D/D |
(660) |
81,152 |
|
8% |
|
Mohideen Pharis |
Chief Medical Officer |
|
2024-05-22 |
4 |
S |
$1.38 |
$527 |
D/D |
(382) |
81,812 |
|
9% |
|
Tasse Daniel |
CHIEF EXECUTIVE OFFICER |
|
2024-03-08 |
4 |
B |
$0.83 |
$14,188 |
D/D |
17,094 |
17,094 |
0.01 |
-35% |
|
Ndu Adora |
|
|
2024-02-06 |
4 |
B |
$0.89 |
$1,624 |
D/D |
1,825 |
1,825 |
0.01 |
-37% |
|
Mohideen Pharis |
Chief Medical Officer |
|
2023-11-22 |
4 |
S |
$1.74 |
$3,906 |
D/D |
(2,245) |
82,194 |
|
13% |
|
Mohideen Pharis |
Chief Medical Officer |
|
2023-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
84,439 |
|
- |
|
Boucinha Virginie |
Chief Financial Officer |
|
2023-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
19,000 |
19,000 |
|
- |
|
Morris Timothy E |
Director |
|
2023-08-25 |
4 |
B |
$1.52 |
$18,240 |
D/D |
12,000 |
12,000 |
2.39 |
-39% |
|
Soland Daniel B |
Director |
|
2023-08-01 |
4 |
B |
$1.62 |
$24,300 |
D/D |
15,000 |
20,000 |
2.39 |
-51% |
|
Mohideen Pharis |
Chief Medical Officer |
|
2023-05-24 |
4 |
S |
$3.54 |
$1,660 |
D/D |
(469) |
49,439 |
|
34% |
|
Mohideen Pharis |
Chief Medical Officer |
|
2022-11-24 |
4 |
S |
$2.88 |
$5,161 |
D/D |
(1,792) |
49,908 |
|
-26% |
|
Robitaille Sebastien |
Chief Financial Officer |
|
2022-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
36,500 |
|
- |
|
Mohideen Pharis |
Chief Medical Officer |
|
2022-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
51,700 |
|
- |
|
Mohideen Pharis |
Chief Medical Officer |
|
2022-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
34,200 |
|
- |
|
Baker Brothers Life Sciences Lp |
Director |
|
2022-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
11,875,000 |
14,575,984 |
|
- |
|
Mohideen Pharis |
Chief Medical Officer |
|
2021-11-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,700 |
24,200 |
|
- |
|
De Rosen Michel |
Director |
|
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,570 |
|
118% |
|
Bjerke Torbjorn |
Director |
|
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,925 |
|
118% |
|
Monges Viviane |
Director |
|
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
600 |
|
118% |
|
Soland Daniel B |
Director |
|
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
118% |
|
Robitaille Sebastien |
Chief Financial OfficerOfficer |
|
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,500 |
|
118% |
|
Baker Julian |
Director |
|
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,286,038 |
|
118% |
|
Mohideen Pharis |
Chief Medical OfficerOfficer |
|
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,500 |
|
118% |
|
23 Records found
|
1
|
Page 1 of 1 |
|
|